Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 11 hours ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

Heart Failure

Prevention & Chronic Conditions
TCT 25: VICTORY Trial: Intravascular Lithotripsy vs Super-High-Pressure Balloons for Calcified Coronary Lesions
Author(s): Matthias Bossard Added: 2 weeks ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus… View more

Intervention

MI/ACS
TAVI in Pure AR
Author(s): Deniz Mutlu , Ibrahim Halil Inanc , Ozgecan Piril Zanbak Mutlu , et al Added: 1 year ago

Intervention
TCT 25 Structural Interventions Highlights
Author(s): Nadira Hamid , Rahul P Sharma Added: 2 weeks ago
TCT 2025 — Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr Rahul P Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and… View more

Intervention
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 7 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 2 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 2 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 24: The KRAKEN Trial
Author(s): Stephen Nicholls Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).KRAKEN is a phase 2, randomized, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 24: The LIBerate-OLE Trial
Author(s): Dean J Kereiakes Added: 12 months ago
AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE … View more

Prevention & Chronic Conditions